New York State Common Retirement Fund Sells 15,584 Shares of CareDx, Inc (NASDAQ:CDNA)

New York State Common Retirement Fund trimmed its holdings in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 48.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 16,339 shares of the company's stock after selling 15,584 shares during the period. New York State Common Retirement Fund's holdings in CareDx were worth $350,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Principal Financial Group Inc. lifted its holdings in CareDx by 6.5% during the 4th quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock valued at $406,000 after purchasing an additional 1,151 shares during the last quarter. Rhumbline Advisers lifted its holdings in CareDx by 1.8% during the 4th quarter. Rhumbline Advisers now owns 81,201 shares of the company's stock valued at $1,738,000 after purchasing an additional 1,451 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in CareDx by 59.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 327,343 shares of the company's stock valued at $7,008,000 after purchasing an additional 122,356 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in CareDx by 6.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 29,107 shares of the company's stock valued at $623,000 after purchasing an additional 1,816 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in CareDx by 31.0% during the 4th quarter. SG Americas Securities LLC now owns 24,087 shares of the company's stock valued at $516,000 after purchasing an additional 5,706 shares during the last quarter.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Stephens reissued an "overweight" rating and set a $40.00 price target on shares of CareDx in a report on Thursday, February 27th. Wells Fargo & Company upgraded shares of CareDx from an "underweight" rating to an "equal weight" rating and lowered their price objective for the company from $28.00 to $24.00 in a research report on Wednesday, January 15th. HC Wainwright lowered their price objective on shares of CareDx from $26.00 to $25.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Finally, StockNews.com upgraded shares of CareDx from a "hold" rating to a "buy" rating in a research report on Wednesday, February 26th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $31.83.

CareDx Trading Up 0.1 %

Shares of NASDAQ:CDNA traded up $0.02 during trading on Friday, hitting $18.92. 998,442 shares of the company's stock were exchanged, compared to its average volume of 843,898. CareDx, Inc has a 1-year low of $7.42 and a 1-year high of $34.84. The firm has a 50-day moving average price of $22.56 and a two-hundred day moving average price of $24.87. The firm has a market cap of $1.01 billion, a P/E ratio of -7.01 and a beta of 1.87.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 EPS for the quarter, topping the consensus estimate of $0.05 by $1.46. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The company had revenue of $86.58 million during the quarter, compared to analysts' expectations of $84.56 million. As a group, research analysts predict that CareDx, Inc will post -0.9 EPS for the current year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.